Current and future imaging modalities for multiple myeloma and its precursor states
Esther Tan1, Brendan M Weiss, Esther Mena
1Multiple Myeloma Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. esther.tan@us.army.mil
Leukemia & Lymphoma
|June 9, 2011
Summary
Novel imaging techniques like CT, MRI, and PET/CT offer superior detection of multiple myeloma bone disease compared to traditional skeletal surveys. These advanced methods also assess treatment response and provide prognostic insights.
Area of Science:
- Oncology
- Radiology
- Medical Imaging
Background:
- Traditional skeletal surveys are limited in detecting osteolytic bone disease in multiple myeloma.
- This modality fails to identify extramedullary lesions, focal bone marrow involvement, and measure treatment response.
Observation:
- Novel imaging techniques including computed tomography (CT), magnetic resonance imaging (MRI), and molecular imaging (PET/CT) show promise.
- Fluorine-18 fluorodeoxyglucose positron emission tomography CT ((18)F-FDG PET/CT) and fluorine-18 sodium fluoride positron emission tomography CT ((18)F-NaF PET/CT) offer enhanced detection capabilities.
- Dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) can measure vascular permeability, a key aspect of myelomagenesis.
Findings:
- Advanced imaging modalities overcome the limitations of skeletal surveys in multiple myeloma detection.
- These techniques provide prognostic information for precursor states and multiple myeloma itself.
- DCE MRI offers insights into myelomagenesis through vascular permeability assessment.
Implications:
- Novel imaging techniques are poised to become essential tools in the management of multiple myeloma.
- These methods improve diagnostic accuracy, treatment monitoring, and prognostication.
- Future research should focus on integrating these advanced modalities into clinical practice for better patient outcomes.
